The data are pretty clear at this point. Across trials for Parkinson's, depression, and chronic pain, patients responding to placebo don't just report feeling better — their dopamine spikes, their endorphins rise, their immune profiles shift. The body isn't being fooled. It's responding.

Now apply this to longevity. We're measuring biomarkers — epigenetic clocks, inflammatory cytokines, mitochondrial function — in people who believe they're being treated. How much of our "anti-aging signal" is just the brain telling the body it's going to be okay?

Hypothesis A: The Nullification Paradigm — Placebo responses are noise. The goal remains isolating pure pharmacological effect from psychological confound. We design cleaner trials, better placebos, more objective endpoints. The biology lives in the molecule, not the mind.

Hypothesis B: The Meaning-Dosing Paradigm — Placebo effects are real biology. Expectation, ritual, and the therapeutic relationship trigger documentable molecular pathways. Rather than controlling for meaning, we prescribe it. We stop subtracting the effect and start optimizing it.

My take? The nullification paradigm is already losing. A 2022 meta-analysis in Nature showed that participant expectation accounts for up to 30% of treatment effect size in age-related trials measuring inflammatory markers. The IL-6 reductions in placebo arms aren't imagination — they're biological.

But here's what bugs me: no funding body will touch this. "Dose the patient with meaning" isn't a fundable grant aim. We're letting ideology — the insistence that only molecules count — blind us to the most cost-effective intervention we have.

Which hypothesis wins? Probably A, for now. But if someone figures out how to systematically harness expectation as a biomarker-modulating tool, they'll outperform every senolytic trial running right now.

We need pilots. We need skeptics to try. Who's willing to be wrong with me?